[Bloomberg BNA] How Will Medicaid Plans Cover Specialty Drugs?

Oct 15, 2014

According to a recent survey from the Kaiser Family Foundation, almost every state Medicaid plan is concerned about the rising cost of specialty drugs — specifically Sovaldi. Sovaldi is a hepatitis c drug from Gilead Sciences which costs  $1,000 a pill, or $84,000 for a 12-week treatment—prices which the plans have balked at. But the drug has a cure rate up to 92 percent. In early October, Gilead received FDA approval on its next-generation hepatitis C drug, Harvoni. That drug delivers cure rates of 94 to 99 percent, but comes with a similarly high price tag of $31,500 a month. Plans have said the costs will break the bank; but at the same time, they can’t deny beneficiaries access to a drug that will cure the disease.

[button title=”Read More” link=”http://www.bna.com/medicaid-plans-cover-b17179896970/” target=”_blank” size=”” color=”” class=””]